To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease
The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a specific enzyme called “Abl” (an enzyme is a biological molecule that accelerates certain chemical reactions in the body). Research has shown that over activation of Abl may play a role in the progression of Parkinson’s disease. Therefore, by limiting or blocking Abl, it may be possible to slow the progression of PD.
- Are 50 years or older
- Have been diagnosed with PD with symptoms beginning in the past three years
- Have not taken PD medication for more than 30 days at any time in the past
What to Expect:
- Study-related care
- Study visits
- Study drugs (investigational drug or placebo)
To learn more contact:
Dr Anupama Kale
email@example.com or 716-819-4117
The investigational drug is not approved by Health Authorities including the US Food and Drug Administration (FDA) for the treatment of Parkinson’s disease
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.